13.42 0.00 (0.00%)
After hours: 4:39PM EDT
|Bid||13.36 x 800|
|Ask||18.11 x 1800|
|Day's Range||13.26 - 13.62|
|52 Week Range||11.66 - 19.19|
|Beta (3Y Monthly)||0.62|
|PE Ratio (TTM)||2.76|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.80|
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Oxford Immunotec Global PLC (OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it has appointed Patrick J. Balthrop, Sr. as Chairman of its board of directors. The current Chairman, Mr. Richard A. Sandberg, will remain a member of the board. “On behalf of the Company and the board of directors I would like to thank our former Chairman, Richard Sandberg, for his service,” said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec.
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
In 2002 Peter Wrighton-Smith was appointed CEO of Oxford Immunotec Global PLC (NASDAQ:OXFD). This report will, first...
AMN Healthcare (AMN) completes Advanced Medical buyout that will help the former to boost offerings in some of the fastest growing and very important care settings.
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.
Oxford Immunotec Global PLC (OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it welcomes the updated Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019, published by the U.S. Centers for Disease Control and Prevention (CDC)1.
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 14, 2019 -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today.
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 70.00% and 6.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Abingdon, Britain-based company said it had a loss of 6 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Oxford Immunotec Global Plc (NASDAQ: OXFD ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:00 AM ...
Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 25, 2019 -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today.
Oxford Immunotec Global PLC is a high-growth diagnostics company. Oxford Immunotec Global PLC had annual average EBITDA growth of 26.00% over the past five years. Warning! GuruFocus has detected 3 Warning Sign with OXFD.
Oxford Immunotec Global PLC (OXFD) (the "Company"), a global, high-growth diagnostics company, today announced a new local production initiative to bring the benefits of the T-SPOT®.TB test to the Russian Federation. Since the T-SPOT.TB test received approval in the Russian Federation in 2013, Oxford Immunotec has been working with a local distribution partner, PharmLine LLC (“PharmLine”) and has seen expanding uptake of the T-SPOT.TB test. In collaboration with PharmLine, Oxford Immunotec will now also be working with Generium Joint Stock Company (“Generium”), who will be manufacturing the T-SPOT.TB test locally at their factory in the Vladimir region of the Russian Federation.
Oxford Immunotec (OXFD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Oxford Immunotec Global PLC (OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that Richard Altieri, the Company’s Chief Financial Officer (CFO), will retire on April 30, 2019. The Company has appointed Matthew McLaughlin, currently Chief Financial Officer, GE Healthcare – U.S. and Canada, as his successor. Mr. McLaughlin will join Oxford Immunotec as CFO on April 8, 2019.
Zacks.com featured highlights include: Great Lakes, Oxford Immunotec, DSP, Telenav and Osisko
Oxford Immunotec Global PLC (OXFD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.